Panitumumab (ABX-EGF)

DRUG3 trials

Sponsors

Amgen

Conditions

Advanced Renal Cell CarcinomaColorectal CancerNon-Small Cell Lung CancerOncologyProstate CancerSolid TumorsTumors

Phase 1

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

CompletedNCT00091806

AmgenOncology, Solid Tumors, Tumors

Start: 2004-08-31End: 2006-10-31Updated: 2009-07-10

Phase 2

Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

CompletedNCT00425204

AmgenAdvanced Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer +2

Start: 2004-03-31End: 2008-03-31Updated: 2008-09-15

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

CompletedNCT00425035

AmgenAdvanced Renal Cell Carcinoma

Start: 2003-02-28Target: 115Updated: 2013-05-13